Market Research Logo

Schizophrenia Global Clinical Trials Review, H2, 2016

Schizophrenia Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Schizophrenia Global Clinical Trials Review, H2, 2016 provides an overview of Schizophrenia clinical trials scenario. This report provides top line data relating to the clinical trials on Schizophrenia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Report Guidance
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Schizophrenia to Central Nervous System Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Schizophrenia to Central Nervous System Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Schizophrenia Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Schizophrenia
Oct 03, 2016: Alkermes Announces Initiation of Clinical Study Evaluating Metabolic Profile of ALKS 3831 for Treatment of Schizophrenia
Sep 28, 2016: Intra-Cellular Therapies Announces Top-Line Results from the Second Phase 3 Trial of ITI-007 in Patients with Schizophrenia (Study ‘302)
Sep 26, 2016: Minerva Neurosciences Provides Update on MIN-101 Clinical Program
Sep 16, 2016: Sunovion to Present Data on Latuda (lurasidone) at the 29th European College of Neuropsychopharmacology (ECNP) Congress
Sep 12, 2016: Karuna Doses First Subject in Tolerability Proof-of-Concept Study of Lead Product Candidate
Aug 08, 2016: Sunovion Announces Publication of Data Evaluating Dose Escalation of Latuda® (lurasidone HCl) in the Treatment of Schizophrenia
Aug 05, 2016: Allergan and Richter Provide Update on Cariprazine Program
Aug 01, 2016: Autifony Therapeutics successfully completes Phase I study of AUT00206, a first-in-class Kv3 modulator for schizophrenia
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Disclaimer
Source
List of Tables
Schizophrenia Therapeutics, Global, Clinical Trials by Region, 2016*
Schizophrenia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
Schizophrenia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
Schizophrenia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
Schizophrenia Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
Schizophrenia Therapeutics Clinical Trials, North America, Top Countries, 2016*
Schizophrenia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016*
Schizophrenia Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*
Proportion of Schizophrenia to Central Nervous System Clinical Trials, G7 Countries (%), 2016*
Schizophrenia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
Schizophrenia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
Proportion of Schizophrenia to Central Nervous System Clinical Trials, E7 Countries (%), 2016*
Schizophrenia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
Schizophrenia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
Schizophrenia Therapeutics, Global, Clinical Trials by Phase, 2016*
Schizophrenia Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
Schizophrenia Therapeutics, Global, Clinical Trials by Trial Status, 2016*
Schizophrenia Therapeutics Clinical Trials, Global, by End Point Status, 2016*
Schizophrenia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
Schizophrenia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
Schizophrenia Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
Schizophrenia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
Schizophrenia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
List of Figures
Schizophrenia Therapeutics, Global, Clinical Trials by Region (%), 2016*
Schizophrenia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
Schizophrenia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
Schizophrenia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
Schizophrenia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
Schizophrenia Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
Schizophrenia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016*
Schizophrenia Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*
Proportion of Schizophrenia to Central Nervous System Clinical Trials, G7 Countries (%), 2016*
Schizophrenia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
Schizophrenia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
Proportion of Schizophrenia to Central Nervous System Clinical Trials, E7 Countries (%), 2016*
Schizophrenia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
Schizophrenia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
Schizophrenia Therapeutics, Global, Clinical Trials by Phase (%), 2016*
Schizophrenia Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
Schizophrenia Therapeutics, Global, Clinical Trials by Trial Status, 2016*
Schizophrenia Therapeutics Clinical Trials, Global, by End Point Status, 2016*
Schizophrenia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
Schizophrenia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
Schizophrenia Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
Schizophrenia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
Schizophrenia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
GlobalData Methodology

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report